within Pharmacolibrary.Drugs.ATC.B;

model B02AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.052,
    Cl             = 0.0004783333333333333,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0177,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B02AB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Camostat mesylate is a serine protease inhibitor used primarily as a treatment for chronic pancreatitis and postoperative reflux esophagitis. It is approved in Japan and some other countries but not widely approved or used in the US or Europe. Camostat has also been studied for potential use in viral infections including COVID-19 due to its ability to inhibit TMPRSS2.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult male volunteers after a single oral dose of camostat mesylate.</p><h4>References</h4><ol><li><p>Kitagawa, J, et al., &amp; Uemura, N (2021). A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19. <i>Clinical and translational science</i> 14(5) 1967–1976. DOI:<a href=&quot;https://doi.org/10.1111/cts.13052&quot;>10.1111/cts.13052</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33982445/&quot;>https://pubmed.ncbi.nlm.nih.gov/33982445</a></p></li><li><p>Beckh, K, et al., &amp; Adler, G (1991). Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate. <i>International journal of pancreatology : official journal of the International Association of Pancreatology</i> 10(3-4) 197–205. DOI:<a href=&quot;https://doi.org/10.1007/BF02924157&quot;>10.1007/BF02924157</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1787334/&quot;>https://pubmed.ncbi.nlm.nih.gov/1787334</a></p></li><li><p>Del Curto, MD, et al., &amp; Sangalli, ME (2011). Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds. <i>Journal of pharmaceutical sciences</i> 100(8) 3251–3259. DOI:<a href=&quot;https://doi.org/10.1002/jps.22560&quot;>10.1002/jps.22560</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21465487/&quot;>https://pubmed.ncbi.nlm.nih.gov/21465487</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B02AB04;
